{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T03:56:58Z","timestamp":1788753418596,"version":"build-2803163510"},"reference-count":82,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T00:00:00Z","timestamp":1666742400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JoF"],"abstract":"<jats:p>Acute lymphoblastic leukemia (ALL) patients comprise a highly immunocompromised group due to factors associated either with the treatment or the disease itself. Invasive mold infections (IMIs) are considered to be responsible for higher morbidity and mortality rates in patients with hematologic malignancies, including ALL. Defining the exact incidence of IMIs in ALL patients has been rather complicated. The available literature data report a highly variable incidence of IMIs, ranging from 2.2% to 15.4%. Although predisposing factors for IMIs in the setting of ALL are ill-defined, retrospective studies have indicated that a longer duration of neutropenia, treatment with high-dose corticosteroids, and a lack of antimold prophylaxis are associated with an increased risk of IMIs. Additionally, the influence of novel ALL treatments on the susceptibility to fungal infections remains obscure; however, initial data suggest that these treatments may induce prolonged neutropenia and thus an increased risk of IMIs. Administering primary antimold prophylaxis in these patients has been challenging since incorporating azole antifungal agents is troublesome, considering the drug-to-drug interactions (DDIs) and increased toxicity that may occur when these agents are coadministered with vincristine, a fundamental component of ALL chemotherapy regimens. Isavuconazole, along with several novel antifungal agents such as rezafungin, olorofim, and manogepix, may be appealing as primary antimold prophylaxis, given their broad-spectrum activity and less severe DDI potential. However, their use in ALL patients needs to be investigated through more clinical trials. In summary, this review outlines the epidemiology of IMI and the use of antifungal prophylaxis in ALL patients.<\/jats:p>","DOI":"10.3390\/jof8111127","type":"journal-article","created":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T05:11:33Z","timestamp":1666761093000},"page":"1127","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Acute Lymphoblastic Leukemia and Invasive Mold Infections: A Challenging Field"],"prefix":"10.3390","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3918-4401","authenticated-orcid":false,"given":"Christos","family":"Stafylidis","sequence":"first","affiliation":[{"name":"First Department of Internal Medicine, Laikon General Hospital, National & Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2692-5944","authenticated-orcid":false,"given":"Panagiotis","family":"Diamantopoulos","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine, Laikon General Hospital, National & Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Athanasoula","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine, Laikon General Hospital, National & Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Solomou","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Patras Medical School, 26500 Rion, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amalia","family":"Anastasopoulou","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine, Laikon General Hospital, National & Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,10,26]]},"reference":[{"key":"ref_1","first-page":"1068","article-title":"The epidemiology of fungal infections in patients with hematologic malignancies: The SEIFEM-2004 study","volume":"91","author":"Pagano","year":"2006","journal-title":"Haematologica"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"i5","DOI":"10.1093\/jac\/dkq437","article-title":"Risk assessment and prognostic factors for mould-related diseases in immunocompromised patients","volume":"66","author":"Pagano","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1086\/339202","article-title":"Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients","volume":"34","author":"Marr","year":"2002","journal-title":"Clin. Infect. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1086\/522189","article-title":"Fungal infections in recipients of hematopoietic stem cell transplants: Results of the SEIFEM B-2004 study\u2013Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne","volume":"45","author":"Pagano","year":"2007","journal-title":"Clin. Infect. Dis."},{"key":"ref_5","first-page":"37","article-title":"Invasive fungal infections in a pediatric hematology-oncology department: A 16-year retrospective study","volume":"6","author":"Kazakou","year":"2020","journal-title":"Curr. Med. Mycol."},{"key":"ref_6","first-page":"94","article-title":"Invasive Fungal Infections in Children with Leukemia: Clinical Features and Prognosis","volume":"39","author":"Tufekci","year":"2022","journal-title":"Turk. J. Haematol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/bjh.15798","article-title":"The incidence of invasive fungal infections in children, adolescents and young adults with acute lymphoblastic leukaemia\/lymphoma treated with the UKALL2011 protocol: A multicentre retrospective study","volume":"186","author":"Govender","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1182\/hematology.2020000098","article-title":"Updates in infection risk and management in acute leukemia","volume":"2020","author":"Logan","year":"2020","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.critrevonc.2003.11.003","article-title":"Adult acute lymphoblastic leukaemia","volume":"50","author":"Bassan","year":"2004","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_10","first-page":"419","article-title":"Emerging Monoclonal Antibody Therapy for the Treatment of Acute Lymphoblastic Leukemia","volume":"15","author":"Abuasab","year":"2021","journal-title":"Biologics"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Kyriakidis, I., Vasileiou, E., Rossig, C., Roilides, E., Groll, A.H., and Tragiannidis, A. (2021). Invasive Fungal Diseases in Children with Hematological Malignancies Treated with Therapies That Target Cell Surface Antigens: Monoclonal Antibodies, Immune Checkpoint Inhibitors and CAR T-Cell Therapies. J. Fungi, 7.","DOI":"10.3390\/jof7030186"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1097\/QCO.0000000000000611","article-title":"Azole antifungals and new targeted therapies for hematological malignancy","volume":"32","author":"Lindsay","year":"2019","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.3109\/10428194.2012.740561","article-title":"Incidence and outcomes of invasive fungal disease in adult patients with acute lymphoblastic leukemia treated with hyperfractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone: Implications for prophylaxis","volume":"54","author":"Henden","year":"2013","journal-title":"Leuk. Lymphoma"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1093\/jac\/dkv343","article-title":"Primary antifungal prophylaxis in adult patients with acute lymphoblastic leukaemia: A multicentre audit","volume":"71","author":"Doan","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.3109\/10428194.2016.1154957","article-title":"Invasive fungal diseases in patients with acute lymphoid leukemia","volume":"57","author":"Nicolato","year":"2016","journal-title":"Leuk. Lymphoma"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1080\/10428194.2016.1204652","article-title":"Epidemiology of invasive fungal infections during induction therapy in adults with acute lymphoblastic leukemia: A GRAALL-2005 study","volume":"58","author":"Mariette","year":"2017","journal-title":"Leuk. Lymphoma"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1080\/10428194.2016.1267351","article-title":"High risk of invasive fungal infections in adult acute lymphoblastic leukemia patients receiving induction and salvage chemotherapy","volume":"58","author":"Keng","year":"2017","journal-title":"Leuk. Lymphoma"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.ijantimicag.2016.10.019","article-title":"Epidemiology of invasive aspergillosis and azole resistance in patients with acute leukaemia: The SEPIA Study","volume":"49","author":"Koehler","year":"2017","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1093\/jac\/dkx133","article-title":"Randomized comparison of liposomal amphotericin B versus placebo to prevent invasive mycoses in acute lymphoblastic leukaemia","volume":"72","author":"Cornely","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1080\/10428194.2019.1613535","article-title":"Invasive pulmonary aspergillosis in acute leukemia: A still frequent condition with a negative impact on the overall treatment outcome","volume":"60","author":"Cattaneo","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s00277-018-3252-6","article-title":"Febrile events in acute lymphoblastic leukemia: A prospective observational multicentric SEIFEM study (SEIFEM-2012\/B ALL)","volume":"97","author":"Cattaneo","year":"2018","journal-title":"Ann. Hematol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Valentine, J.C., Morrissey, C.O., Tacey, M.A., Liew, D., Patil, S., Peleg, A.Y., and Ananda-Rajah, M.R. (2019). A population-based analysis of invasive fungal disease in haematology-oncology patients using data linkage of state-wide registries and administrative databases: 2005\u20132016. BMC Infect. Dis., 19.","DOI":"10.1186\/s12879-019-3901-y"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1080\/10428194.2019.1590570","article-title":"Auditing fungal disease in leukemia patients in a tertiary care center: Opportunities and challenges for an antifungal stewardship program","volume":"60","author":"Paige","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1111\/myc.13151","article-title":"Invasive fungal diseases in patients with new diagnosed acute lymphoblastic leukaemia","volume":"63","author":"Grundahl","year":"2020","journal-title":"Mycoses"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"22160","DOI":"10.1038\/s41598-021-01716-2","article-title":"Incidence of invasive fungal infection in acute lymphoblastic and acute myelogenous leukemia in the era of antimold prophylaxis","volume":"11","author":"Oh","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","article-title":"Revision and Update of the Consensus Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium","volume":"71","author":"Donnelly","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.cmi.2022.02.026","article-title":"The impact of the updated EORTC\/MSG criteria on the classification of hematological patients with suspected invasive pulmonary aspergillosis","volume":"28","author":"Lamberink","year":"2022","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"101304","DOI":"10.1016\/j.mycmed.2022.101304","article-title":"Impact of revised EORTC\/MSGERC 2020 criteria on diagnosis and prognosis of invasive pulmonary aspergillosis in patients with hematological malignancies undergoing bronchoscopy","volume":"32","author":"Ozturk","year":"2022","journal-title":"J. Mycol. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/imj.15588","article-title":"Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2021","volume":"51","author":"Teh","year":"2021","journal-title":"Intern. Med. J."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/sj.bmt.1705181","article-title":"Protective role of interleukin-10 promoter gene polymorphism in the pathogenesis of invasive pulmonary aspergillosis after allogeneic stem cell transplantation","volume":"36","author":"Seo","year":"2005","journal-title":"Bone Marrow Transplant."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.humimm.2006.10.011","article-title":"Variable number of tandem repeats of TNF receptor type 2 promoter as genetic biomarker of susceptibility to develop invasive pulmonary aspergillosis","volume":"68","author":"Sainz","year":"2007","journal-title":"Hum. Immunol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1056\/NEJMoa0802629","article-title":"Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation","volume":"359","author":"Bochud","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Zaas, A.K., Liao, G., Chien, J.W., Weinberg, C., Shore, D., Giles, S.S., Marr, K.A., Usuka, J., Burch, L.H., and Perera, L. (2008). Plasminogen alleles influence susceptibility to invasive aspergillosis. PLoS Genet., 4.","DOI":"10.1371\/journal.pgen.1000101"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1086\/644619","article-title":"Association of mannose-binding lectin deficiency with acute invasive aspergillosis in immunocompromised patients","volume":"49","author":"Lambourne","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"5394","DOI":"10.1182\/blood-2010-04-279307","article-title":"Dectin-1 Y238X polymorphism associates with susceptibility to invasive aspergillosis in hematopoietic transplantation through impairment of both recipient- and donor-dependent mechanisms of antifungal immunity","volume":"116","author":"Cunha","year":"2010","journal-title":"Blood"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1111\/j.1469-0691.2009.03015.x","article-title":"Pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: Incidence, risk factors, and outcome","volume":"16","author":"Guinea","year":"2010","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.1182\/blood-2014-04-516211","article-title":"How we treat invasive fungal diseases in patients with acute leukemia: The importance of an individualized approach","volume":"124","author":"Nucci","year":"2014","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1001\/jama.284.22.2869","article-title":"Fungal contamination of tobacco and marijuana","volume":"284","author":"Verweij","year":"2000","journal-title":"JAMA"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1002\/cncr.22909","article-title":"Increased bone marrow iron stores is an independent risk factor for invasive aspergillosis in patients with high-risk hematologic malignancies and recipients of allogeneic hematopoietic stem cell transplantation","volume":"110","author":"Kontoyiannis","year":"2007","journal-title":"Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1086\/652761","article-title":"Geoclimatic influences on invasive aspergillosis after hematopoietic stem cell transplantation","volume":"50","author":"Panackal","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1439-0507.2011.02073.x","article-title":"Airborne fungus exposure prior to hospitalisation as risk factor for mould infections in immunocompromised patients","volume":"55","author":"Blum","year":"2012","journal-title":"Mycoses"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.ajic.2009.09.014","article-title":"The impact of portable high-efficiency particulate air filters on the incidence of invasive aspergillosis in a large acute tertiary-care hospital","volume":"38","author":"Karlin","year":"2010","journal-title":"Am. J. Infect. Control"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3849","DOI":"10.1200\/JCO.2008.21.0856","article-title":"Index to predict invasive mold infection in high-risk neutropenic patients based on the area over the neutrophil curve","volume":"27","author":"Portugal","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Stanzani, M., and Lewis, R.E. (2018). Development and Applications of Prognostic Risk Models in the Management of Invasive Mold Disease. J. Fungi, 4.","DOI":"10.3390\/jof4040141"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e3606","DOI":"10.1093\/cid\/ciaa1065","article-title":"Epidemiology of Invasive Pulmonary Aspergillosis Among Intubated Patients With COVID-19: A Prospective Study","volume":"73","author":"Bartoletti","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e543","DOI":"10.1016\/S2666-5247(21)00237-8","article-title":"The emergence of COVID-19 associated mucormycosis: A review of cases from 18 countries","volume":"3","author":"Hoenigl","year":"2022","journal-title":"Lancet Microbe"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e0009421","DOI":"10.1128\/CMR.00094-21","article-title":"Pathogenesis of Respiratory Viral and Fungal Coinfections","volume":"35","author":"Salazar","year":"2022","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e149","DOI":"10.1016\/S1473-3099(20)30847-1","article-title":"Defining and managing COVID-19-associated pulmonary aspergillosis: The 2020 ECMM\/ISHAM consensus criteria for research and clinical guidance","volume":"21","author":"Koehler","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Rajic, J., Gmizic, I., Gunjak, T., Milosevic, V., Pantic, N., Sabljic, N., Mitrovic, M., Djuric Stefanovic, A., Lazic, L., and Jovanovic, S. (2021). COVID-19-Associated Pulmonary Aspergillosis in Patients with Acute Leukemia: A Single-Center Study. J. Fungi, 7.","DOI":"10.3390\/jof7110890"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Madney, Y., Shalaby, L., Hammad, M., Elanany, M., Hassan, R., Youssef, A., Abdo, I., Zaki, A., and Khedr, R. (2022). COVID-19-Associated Pulmonary Fungal Infection among Pediatric Cancer Patients, a Single Center Experience. J. Fungi, 8.","DOI":"10.3390\/jof8080850"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1002\/cncr.32116","article-title":"Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study","volume":"125","author":"Kantarjian","year":"2019","journal-title":"Cancer"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S1470-2045(18)30011-1","article-title":"Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: A single-arm, phase 2 study","volume":"19","author":"Kantarjian","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: A multicentre, single-arm, phase 2 study","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/j.cmi.2018.02.003","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: An infectious diseases perspective (Agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52)","volume":"24","author":"Mikulska","year":"2018","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1038\/s41409-019-0487-3","article-title":"Early and late hematologic toxicity following CD19 CAR-T cells","volume":"54","author":"Fried","year":"2019","journal-title":"Bone Marrow Transplant."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/blood-2017-07-793760","article-title":"Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy","volume":"131","author":"Hill","year":"2018","journal-title":"Blood"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/cid\/ciy152","article-title":"Cytokine Release Syndrome Grade as a Predictive Marker for Infections in Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Treated With Chimeric Antigen Receptor T Cells","volume":"67","author":"Park","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/cid\/ciz1127","article-title":"Invasive Mold Infections After Chimeric Antigen Receptor-Modified T-Cell Therapy: A Case Series, Review of the Literature, and Implications for Prophylaxis","volume":"71","author":"Haidar","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1200\/JCO.18.00374","article-title":"Antimicrobial Prophylaxis for Adult Patients with Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update","volume":"36","author":"Taplitz","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1111\/myc.12786","article-title":"How to prophylax against invasive fungal infections in adult ALL? An unmet need","volume":"61","author":"Cornely","year":"2018","journal-title":"Mycoses"},{"key":"ref_62","first-page":"2416","article-title":"Vincristine-induced peripheral neuropathy in pediatric cancer patients","volume":"6","author":"Mora","year":"2016","journal-title":"Am. J. Cancer Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1093\/jac\/dkr223","article-title":"Effect of azole antifungal therapy on vincristine toxicity in childhood acute lymphoblastic leukaemia","volume":"66","author":"Bruggemann","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e273","DOI":"10.1097\/MPH.0000000000001220","article-title":"Vincristine-associated Neuropathy with Antifungal Usage: A Kaiser Northern California Experience","volume":"40","author":"Nikanjam","year":"2018","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Van de Velde, M.E., Kaspers, G.J.L., Abbink, F.C.H., Twisk, J.W.R., van der Sluis, I.M., van den Bos, C., van den Heuvel-Eibrink, M.M., Segers, H., Chantrain, C., and van der Werff Ten Bosch, J. (2020). Vincristine-Induced Peripheral Neuropathy in Pediatric Oncology: A Randomized Controlled Trial Comparing Push Injections with One-Hour Infusions (The VINCA Trial). Cancers, 12.","DOI":"10.3390\/cancers12123745"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1182\/blood-2003-07-2512","article-title":"Cyclophosphamide metabolism is affected by azole antifungals","volume":"103","author":"Marr","year":"2004","journal-title":"Blood"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1097\/FTD.0b013e31815c16f5","article-title":"Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring","volume":"29","author":"Zhou","year":"2007","journal-title":"Ther. Drug Monit."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1093\/cid\/civ571","article-title":"Isavuconazole: A New Broad-Spectrum Triazole Antifungal Agent","volume":"61","author":"Miceli","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/myc.12731","article-title":"Isavuconazole shortens the QTc interval","volume":"61","author":"Mellinghoff","year":"2018","journal-title":"Mycoses"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1093\/mmy\/myab025","article-title":"Efficacy and safety of isavuconazole compared with voriconazole as primary antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients","volume":"59","author":"Bogler","year":"2021","journal-title":"Med. Mycol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1093\/cid\/ciaa652","article-title":"Isavuconazole Is as Effective as and Better Tolerated Than Voriconazole for Antifungal Prophylaxis in Lung Transplant Recipients","volume":"73","author":"Samanta","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1093\/cid\/ciaa358","article-title":"Isavuconazole as Primary Antifungal Prophylaxis in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-label, Prospective, Phase 2 Study","volume":"72","author":"Bose","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1093\/cid\/ciz282","article-title":"Isavuconazole Prophylaxis in Patients with Hematologic Malignancies and Hematopoietic Cell Transplant Recipients","volume":"70","author":"Fontana","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1080\/16078454.2022.2076046","article-title":"Effectiveness and safety of isavuconazole prophylaxis for invasive fungal infections in the haematologic setting","volume":"27","author":"Ping","year":"2022","journal-title":"Hematology"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"i60","DOI":"10.1093\/jac\/dkx450","article-title":"Echinocandin prophylaxis in patients undergoing haematopoietic cell transplantation and other treatments for haematological malignancies","volume":"73","author":"Epstein","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1128\/JCM.01155-09","article-title":"In vitro susceptibility of clinical isolates of Aspergillus spp. to anidulafungin, caspofungin, and micafungin: A head-to-head comparison using the CLSI M38-A2 broth microdilution method","volume":"47","author":"Pfaller","year":"2009","journal-title":"J. Clin. Microbiol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s10096-014-2287-4","article-title":"Efficacy and safety of echinocandins versus triazoles for the prophylaxis and treatment of fungal infections: A meta-analysis of RCTs","volume":"34","author":"Wang","year":"2015","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1055\/s-0039-3400291","article-title":"Antifungal Therapy: New and Evolving Therapies","volume":"41","author":"Nivoix","year":"2020","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1007\/s40265-021-01611-0","article-title":"The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin","volume":"81","author":"Hoenigl","year":"2021","journal-title":"Drugs"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"e01992-20","DOI":"10.1128\/AAC.01992-20","article-title":"Efficacy of Rezafungin in Prophylactic Mouse Models of Invasive Candidiasis, Aspergillosis, and Pneumocystis Pneumonia","volume":"65","author":"Miesel","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Wiederhold, N.P. (2020). Review of the Novel Investigational Antifungal Olorofim. J. Fungi, 6.","DOI":"10.3390\/jof6030122"},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Shaw, K.J., and Ibrahim, A.S. (2020). Fosmanogepix: A Review of the First-in-Class Broad Spectrum Agent for the Treatment of Invasive Fungal Infections. J. Fungi, 6.","DOI":"10.3390\/jof6040239"}],"container-title":["Journal of Fungi"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2309-608X\/8\/11\/1127\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:02:55Z","timestamp":1760144575000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2309-608X\/8\/11\/1127"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,26]]},"references-count":82,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["jof8111127"],"URL":"https:\/\/doi.org\/10.3390\/jof8111127","relation":{},"ISSN":["2309-608X"],"issn-type":[{"value":"2309-608X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,26]]}}}